Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1948 6
1949 1
1950 6
1951 6
1952 2
1953 3
1954 3
1955 3
1956 4
1957 5
1958 2
1959 9
1960 15
1961 6
1962 9
1963 14
1964 24
1965 17
1966 14
1967 11
1968 17
1969 11
1970 26
1971 21
1972 26
1973 38
1974 43
1975 103
1976 119
1977 115
1978 142
1979 212
1980 221
1981 243
1982 293
1983 304
1984 348
1985 426
1986 481
1987 523
1988 573
1989 632
1990 658
1991 672
1992 771
1993 875
1994 988
1995 1004
1996 1143
1997 1356
1998 1490
1999 1644
2000 1744
2001 1889
2002 2187
2003 2383
2004 2704
2005 3059
2006 3333
2007 3578
2008 3949
2009 4370
2010 4836
2011 5361
2012 6070
2013 6851
2014 8044
2015 8803
2016 9208
2017 9912
2018 10803
2019 11719
2020 12727
2021 88
Text availability
Article attribute
Article type
Publication date

Search Results

127,392 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Zong-fu
Page 1
Did you mean zang fu fu (532 results)?
Therapeutic drug monitoring of 5-fluorouracil.
Lee JJ, Beumer JH, Chu E. Lee JJ, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):447-64. doi: 10.1007/s00280-016-3054-2. Epub 2016 May 23. Cancer Chemother Pharmacol. 2016. PMID: 27217046 Free PMC article. Review.
However, it is now well established that BSA-based 5-FU dosing is correlated with a wide variation of 5-FU systemic exposure. ...There is growing evidence to show that 5-FU dosing based on plasma 5-FU drug level is feasible and that 5-FU TDM can …
However, it is now well established that BSA-based 5-FU dosing is correlated with a wide variation of 5-FU systemic exposure. …
Intralesional 5-fluorouracil in keloid treatment: a systematic review.
Bijlard E, Steltenpool S, Niessen FB. Bijlard E, et al. Acta Derm Venereol. 2015 Sep;95(7):778-82. doi: 10.2340/00015555-2106. Acta Derm Venereol. 2015. PMID: 25805099 Free article. Review.
In the 1990s, 5-flourouracil (5-FU) was introduced as a treatment for keloids; however, there is still no consensus on its use. ...Two reviewers selected original research reports using 5-FU alone or combined with a maximum of 2 other therapies. Eighteen papers were …
In the 1990s, 5-flourouracil (5-FU) was introduced as a treatment for keloids; however, there is still no consensus on its use. ...Tw …
Retraction: Nucleophagy in Human Disease: Beyond the Physiological Role. [Tohoku J. Exp. Med., 2018, 244 (1), 75-81. doi: 10.1620/tjem.244.75. Review.].
[No authors listed] [No authors listed] Tohoku J Exp Med. 2018 Feb;244(2):175. doi: 10.1620/tjem.244.175. Tohoku J Exp Med. 2018. PMID: 29467341 Free article.
In addition, the replies from three authors (Ming Zhou, Hongwen Ji and Yong Xia) clearly indicate that they misunderstand the identity of Dr. Nina Fu. We also attempted to contact two authors, named Nian Fu and Linxi Chen, via e-mail. ...According to Dr. Nian Fu
In addition, the replies from three authors (Ming Zhou, Hongwen Ji and Yong Xia) clearly indicate that they misunderstand the identity of Dr …
Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.
Zhang Y, Yang L, Dai G, Cao H. Zhang Y, et al. Int J Clin Exp Pathol. 2018 Dec 1;11(12):5869-5876. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31949673 Free PMC article.
The knockdown of PHGDH made possible the inhibitory effect of 5-FU on the proliferation of BGC823/5-FU cells. Furthermore, 5-FU treatment promoted apoptosis of BGC823/5-FU cells, as indicated by increased numbers of TUNEL-positive cells and increased r …
The knockdown of PHGDH made possible the inhibitory effect of 5-FU on the proliferation of BGC823/5-FU cells. Furthermore, 5- …
5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.
Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, Vincent J, Bengrine-Lefevre L, Ghiringhelli F, Schmitt A. Morawska K, et al. Oncotarget. 2018 Jan 30;9(14):11559-11571. doi: 10.18632/oncotarget.24338. eCollection 2018 Feb 20. Oncotarget. 2018. PMID: 29545919 Free PMC article.
In our study, we evaluated the 5-FU exposure-toxicity relationship and investigated the efficacy of PK-guided dosing in increasing tolerability of 5-FU-based chemotherapy. ...CONCLUSIONS: Our analysis confirms that the use of BSA-guided dosing results in highly vari …
In our study, we evaluated the 5-FU exposure-toxicity relationship and investigated the efficacy of PK-guided dosing in increasing to …
MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells.
Wang CQ. Wang CQ. Eur Rev Med Pharmacol Sci. 2019 May;23(9):3771-3778. doi: 10.26355/eurrev_201905_17803. Eur Rev Med Pharmacol Sci. 2019. PMID: 31115003 Free article.
OBJECTIVE: To investigate the role of micro ribonucleic acid (miR)-195 in acquired resistance to 5-fluorouracil (5-FU) in gastric cancer and its potential mechanism. MATERIALS AND METHODS: The drug resistance of AGS/5-FU and SGC-7901/5-FU cells compared with …
OBJECTIVE: To investigate the role of micro ribonucleic acid (miR)-195 in acquired resistance to 5-fluorouracil (5-FU) in gastric can …
5-FU for genital warts in non-immunocompromised individuals.
Batista CS, Atallah AN, Saconato H, da Silva EM. Batista CS, et al. Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD006562. doi: 10.1002/14651858.CD006562.pub2. Cochrane Database Syst Rev. 2010. PMID: 20393949 Free PMC article. Review.
Worse results were found for 5-FU versus 5-FU + INFalpha-2a (high dose) (RR 10.78, 95% CI 1.50 to 77.36), and 5-FU + CO2 Laser INFalpha-2a (high dose) (RR 7.97, 95% CI 2.87 to 22.13). ...Cure rates with several treatments were variable, and although 5-FU
Worse results were found for 5-FU versus 5-FU + INFalpha-2a (high dose) (RR 10.78, 95% CI 1.50 to 77.36), and 5-FU + CO …
EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression.
Wang C, Li X, Zhang J, Ge Z, Chen H, Hu J. Wang C, et al. Onco Targets Ther. 2018 Nov 5;11:7853-7864. doi: 10.2147/OTT.S180131. eCollection 2018. Onco Targets Ther. 2018. PMID: 30464532 Free PMC article.
EZH2 knockdown enhanced 5-FU sensitivity of AGS/5-FU and SGC-7901/5-FU cells. Moreover, EZH2 could epigenetically suppress FBXO32 expression. FBXO32 overexpression could mimic the functional role of downregulated EZH2 in 5-FU resistance. FBXO32 knockdo …
EZH2 knockdown enhanced 5-FU sensitivity of AGS/5-FU and SGC-7901/5-FU cells. Moreover, EZH2 could epigenetically suppr …
ERRATUM.
Furutani A, Sowa Y, Fujiwara H, Otsuji E, Sakai T. Furutani A, et al. Oncol Res. 2016 Jan 21;23(1):87. doi: 10.3727/096504016X14514194509664. Oncol Res. 2016. PMID: 29021025
Histone deacetylase (HDAC) inhibitors have been shown to enhance the effects of 5-fluorouracil (5-FU) against various cancer cells; however, no report has shown that an HDAC inhibitor may enhance the effects of 5-FU with radiation. ...The inhibition of the cell grow …
Histone deacetylase (HDAC) inhibitors have been shown to enhance the effects of 5-fluorouracil (5-FU) against various cancer cells; h …
miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells.
Meng X, Fu R. Meng X, et al. Onco Targets Ther. 2018 Mar 29;11:1757-1765. doi: 10.2147/OTT.S159093. eCollection 2018. Onco Targets Ther. 2018. PMID: 29636622 Free PMC article.
The current study aimed to explore the potential function of miR-206 in 5-FU resistance. METHODS: To indentify the role of miR-206 in 5-FU resistance, the expression of miR-206 was examined by real-time polymerase chain reaction (RT-PCR) in 5-FU-resistant (FR …
The current study aimed to explore the potential function of miR-206 in 5-FU resistance. METHODS: To indentify the role of miR-206 in …
127,392 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback